We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
It’s back to bench testing for a specialty drug company after the FDA rejected its new drug application for a combination drug and device pain treatment product. Read More
Sponsors of companion diagnostics should submit applications to the FDA simultaneously with the drug product submission to improve the chances that the test on which the treatment relies is available when the drug is approved, an FDA final guidance says. Read More
Concerns about safety and efficacy data from a U.S. clinical trial, insufficient patient follow-up and the questionable culling of data from a European patient registry sank the Ablatherm-HIFU system for treatment of low-risk prostate cancer during a Wednesday FDA advisory panel meeting. Read More